Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Mary M. Rozenman sold 30,000 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $22.50, for a total transaction of $675,000.00. Following the completion of the transaction, the insider now owns 30,129 shares in the company, valued at approximately $677,902.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Aimmune Therapeutics, Inc. (AIMT) opened at 23.36 on Wednesday. The stock has a 50 day moving average of $23.17 and a 200 day moving average of $21.15. Aimmune Therapeutics, Inc. has a 52 week low of $14.11 and a 52 week high of $27.31. The company’s market cap is $1.18 billion.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). Equities research analysts predict that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Mary M. Rozenman Sells 30,000 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/13/mary-m-rozenman-sells-30000-shares-of-aimmune-therapeutics-inc-aimt-stock.html.

Several institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its holdings in shares of Aimmune Therapeutics by 10.1% during the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 499 shares during the period. Teachers Advisors LLC lifted its holdings in Aimmune Therapeutics by 2.4% in the fourth quarter. Teachers Advisors LLC now owns 43,229 shares of the biotechnology company’s stock valued at $884,000 after acquiring an additional 1,025 shares during the period. American International Group Inc. lifted its holdings in Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after acquiring an additional 1,070 shares during the period. Legal & General Group Plc lifted its holdings in Aimmune Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after acquiring an additional 1,634 shares during the period. Finally, Strs Ohio lifted its holdings in Aimmune Therapeutics by 6.1% in the second quarter. Strs Ohio now owns 34,600 shares of the biotechnology company’s stock valued at $711,000 after acquiring an additional 2,000 shares during the period. 72.90% of the stock is owned by hedge funds and other institutional investors.

AIMT has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. ValuEngine cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 27th. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, July 27th. Wedbush reiterated an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Monday, July 24th. Finally, BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $32.50.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.